1. Severely debilitating or life-threatening hematologic disorders: nonclinical development of pharmaceuticals Publication: Silver Spring, MD : Center for Drug Evaluation and Research, March 2019 Subject(s): Drug Evaluation, Preclinical -- standardsHematologic Diseases -- drug therapyAnimalsCarcinogenicity TestsCytotoxicity Tests, ImmunologicDrug Therapy, CombinationDrug-Related Side Effects and Adverse ReactionsImmunologic TestsMutagenicity TestsPediatricsPharmacokineticsPhotochemistrySafetyToxicity TestsHumansUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
